Literature DB >> 16934030

How does hepatitis C virus enter cells?

Gundo Diedrich1.   

Abstract

Hepatitis C virus (HCV) exists in different forms in the circulation of infected people: lipoprotein bound and lipoprotein free, enveloped and nonenveloped. Viral particles with the highest infectivity are associated with lipoproteins, whereas lipoprotein-free virions are poorly infectious. The detection of HCV's envelope proteins E1 and E2 in lipoprotein-associated virions has been challenging. Because lipoproteins are readily endocytosed, some forms of HCV might utilize their association with lipoproteins rather than E1 and E2 for cell attachment and internalization. However, vaccination of chimpanzees with recombinant envelope proteins protected the animals from hepatitis C infection, suggesting an important role for E1 and E2 in cell entry. It seems possible that different forms of HCV use different receptors to attach to and enter cells. The putative receptors and the assays used for their validation are discussed in this review.

Entities:  

Mesh:

Year:  2006        PMID: 16934030     DOI: 10.1111/j.1742-4658.2006.05379.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  11 in total

Review 1.  Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.

Authors:  Giuseppe Danilo Norata; Hagai Tavori; Angela Pirillo; Sergio Fazio; Alberico L Catapano
Journal:  Cardiovasc Res       Date:  2016-08-05       Impact factor: 10.787

2.  Apolipoprotein c1 association with hepatitis C virus.

Authors:  Jean-Christophe Meunier; Rodney S Russell; Ronald E Engle; Kristina N Faulk; Robert H Purcell; Suzanne U Emerson
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

3.  Contribution of redox status to hepatitis C virus E2 envelope protein function and antigenicity.

Authors:  Emmanuel Fenouillet; Dimitri Lavillette; Silvia Loureiro; George Krashias; Guillemette Maurin; François-Loïc Cosset; Ian M Jones; Rym Barbouche
Journal:  J Biol Chem       Date:  2008-07-30       Impact factor: 5.157

Review 4.  Dysmetabolic changes associated with HCV: a distinct syndrome?

Authors:  Amedeo Lonardo; Paola Loria; Nicola Carulli
Journal:  Intern Emerg Med       Date:  2008-02-15       Impact factor: 3.397

5.  Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus.

Authors:  Wei Yang; Chao Qiu; Nabanita Biswas; Jing Jin; Simon C Watkins; Ronald C Montelaro; Carolyn B Coyne; Tianyi Wang
Journal:  J Biol Chem       Date:  2008-01-22       Impact factor: 5.157

6.  Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production.

Authors:  Wei Yang; Brian L Hood; Sara L Chadwick; Shufeng Liu; Simon C Watkins; Guangxiang Luo; Thomas P Conrads; Tianyi Wang
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

7.  New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents.

Authors:  Josep Quer; Maria Buti; Maria Cubero; Jaume Guardia; Rafael Esteban; Juan Ignacio Esteban
Journal:  Infect Drug Resist       Date:  2010-11-23       Impact factor: 4.003

8.  Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2.

Authors:  Yasmine S El Abd; Ashraf A Tabll; Noha G Bader El Din; Alaa El-Dien S Hosny; Rehab I Moustafa; Reem El-Shenawy; Khaled Atef; Mostafa K El-Awady
Journal:  Virol J       Date:  2011-08-05       Impact factor: 4.099

9.  Analysis of a conserved RGE/RGD motif in HCV E2 in mediating entry.

Authors:  Katharina B Rothwangl; Lijun Rong
Journal:  Virol J       Date:  2009-01-26       Impact factor: 4.099

10.  Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding.

Authors:  Katharina B Rothwangl; Balaji Manicassamy; Susan L Uprichard; Lijun Rong
Journal:  Virol J       Date:  2008-03-20       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.